against TFF3 or scrambled siRNA as control. TFF3 (A) mRNA and (B) protein levels in BT474-siSC and -siTFF3 cells were validated by qPCR and western blot with β-ACTIN as input control. (C) BT474-siSC and -siTFF3 cells were cultured in 5% FBS media containing 4% Matrigel and treated with 10 µg/ml trastuzumab over a period of 8 to 10 days. Cell viability in 3D Matrigel was measured by AlamarBlue assay. (D) BT474-siSC and -siTFF3 cells were cultured in 5% FBS media containing 4% Matrigel, and treated with 10 µg/ml trastuzumab, 5 µM tamoxifen or the combination over a period of 8 to 10 days. (E) MDA-MB-361-siSC and -siTFF3 cells were cultured in 10% FBS media containing 4% Matrigel, and treated with 10 µg/ml trastuzumab, 1 µM tamoxifen or the combination over a period of 8 to 10 days.
Release of HER2 repression of trefoil factor 3 (TFF3) expression mediates trastuzumab resistance in HER2+/ER+ mammary carcinoma
concentrations of EGF or HRG for 24 and 48 hours respectively in phenol-red free medium supplemented with 10% charcoal-stripped FBS. Right, BT474 cells were treated with 500 ng/ml of EGF or HRG for the indicated time-points in phenol-red free medium supplemented with 10% charcoal-stripped FBS. (C and D) Left, BT474 cells were treated with the indicated concentrations of EGF or HRG for 48 hours in phenol-red free medium supplemented with 10% charcoal-stripped FBS and exogenous 100 nM 17β-estradiol. Right, BT474 cells were treated with 200 ng/ml of EGF or HRG for the indicated time-points in phenol-red free medium supplemented with 10% charcoal-stripped FBS and exogenous 100 nM 17β-estradiol. (E and F) Left BT474 cells were treated with the indicated concentrations of trastuzumab for 48 hours in phenol-red free medium supplemented with 10% charcoal-stripped FBS ± 100 nM 17β-estradiol. Right, BT474 cells were treated with 10 µg/ml of trastuzumab for the indicated time-points in phenol-red free medium supplemented with 10% charcoal-stripped FBS ± 100 nM 17β-estradiol. TFF3 mRNA level was determined by qPCR, with β-ACTIN as input control. E2: 17β-estradiol; Tras: trastuzumab. In (C), (D) and (F), the statistical significance in differences in TFF3 mRNA levels between the E2 treated cells (2nd bar) as compared to untreated cells (1st bar) is represented by the * symbol. The statistical significance of differences in TFF3 mRNA levels between cells treated with EGF or HRG in the presence of exogenous E2 as compared to cells treated with only E2 (2nd bar) is represented by the # symbol. * or # p < 0.05; ** or HER receptors crosstalk partners and (C) downstream transcription factors, and the levels of (D) cell cycle and apoptosis regulators in BT474-VEC and -TFF3 cells were analysed by western blot. β-ACTIN was used as input control. (E) BT474-siSC and -siTFF3 cells were generated. The levels of TFF3, phosphorylated and total HER receptors and downstream signalling mediators were analysed using western blot. β-ACTIN was used as input control. The densitiometric analyses of protein bands were performed using ImageJ. **p < 0.01.
